Regrowth of Port Wine Stain’s Blood Vessels Cause Unsatisfied Therapeutic Outcome
For Immediate Release
July 23, 2013
Wausau, WI – Wenbin Tan, Ph.D., a graduate of the University of California, is the recipient of an American Society for Laser Medicine and Surgery, Inc. (ASLMS) 2013 Research Grant.
Dr. Tan is a non-student recipient who conducted research on the development of new therapeutic strategies for Port Wine Stain (PWS) birthmarks. The manuscript is titled “Topical Axitinib Combined with Rapamycin to Inhibit the Regrowth of Port Wine Stain Blood Vessels Post Pulsed Dye Laser Treatment”.
In his research, Dr. Tan discovered that the Pulsed Dye Laser (PDL) is the current treatment for PWS but the regrowth of PWS blood vessels cause unsatisfied therapeutic outcomes in patients. In an animal model, he observed that topical application of anti-angiogenic drugs can inhibit blood vessel regrowth post PDL.
“I expect this strategy can be applied to PWS patients to achieve better therapeutic outcomes,” said Dr. Tan.
Since 2007, ASLMS has awarded $1.4 million for research projects. These projects are designed to advance the development and use of lasers and other associated technologies in medical and surgical applications.
The grants were funded by net proceeds received from the silent auction held at the 2012 Annual Conference, Industry Advisory Council memberships and member research contributors.
To learn more about these research grant opportunities or to apply visit www.aslms.org/grants/grants.shtml for details.
- 30 -
hr/wenbin_research_2013
tel 715-301-1634
mobile 715-498-1242
fax 715-848-2493
email matt@aslms.org
web www.aslms.org
The American Society for Laser Medicine and Surgery, Inc. (ASLMS) is the world's largest scientific organization dedicated to promoting research, education and high standards of clinical care in the field of medical laser applications. It provides a forum for the exchange of scientific information and participates in communicating the latest developments in laser medicine and surgery to clinicians, research investigators, government and regulatory agencies, and the public.
Tags: